PerkinElmer Agrees to Acquire Viral Vector Gene Delivery Leader SIRION Biotech

Solutions to complement Company’s growing position in cell and gene therapy research and development WALTHAM, Mass.–(BUSINESS WIRE)–Jun. 22, 2021– PerkinElmer, Inc. (NYSE: PKI) (“PerkinElmer”) is pleased to announce it has entered into an agreement to acquire SIRION Biotech GmbH, a leading, global provider of viral vector-based technologies that drive improved delivery performance for cell and gene... Read more

Avantor Acquires RIM Bio; Expands Bioproduction Footprint into China

Changzhou, China, operations become Avantor’s first single-use production facility in AMEA region; doubles Avantor’s global single-use cleanroom space Adds proprietary technologies to Avantor’s bioprocessing manufacturing capabilities to meet growing global demand for single-use solutions RADNOR, Pa. and SHANGHAI, June 1, 2021 /PRNewswire/ —  Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the... Read more

Pivotal Phase III data at ASCO show Roche’s Tecentriq helps certain people with early lung cancer live significantly longer without their disease returning

Tecentriq improved disease-free survival by more than one-third in people with PD-L1-positive resectable early-stage lung cancer, compared with best supportive care First and only cancer immunotherapy to show positive Phase III results in the adjuvant lung cancer setting New adjuvant treatment options are urgently needed in early lung cancer to help the approximately 50% of... Read more

Bio-Techne and 908 Devices Announce Joint Collaboration

MAY 04, 2021 MINNEAPOLIS and BOSTON, May 4, 2021 /PRNewswire/ — Bio-Techne Corporation (NASDAQ: TECH) and 908 Devices (NASDAQ: MASS) today announced a joint collaboration to develop an extended workflow solution for protein characterization. Bio-Techne, a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities, and owner of the leading ProteinSimple... Read more

Thermo Fisher Scientific Recognizes Significance of FDA Approval of First CAR T Cell Immunotherapy for Multiple Myeloma with Donation to Leukemia and Lymphoma Society

Thermo Fisher Scientific Recognizes Significance of FDA Approval of First CAR T Cell Immunotherapy for Multiple Myeloma with Donation to Leukemia and Lymphoma Society WALTHAM, Mass. (April 28, 2021) — Thermo Fisher Scientific Inc. has made a donation to the Leukemia & Lymphoma Society in recognition of the recent U.S. Food and Drug Administration approval... Read more

Roche receives FDA approval for first companion diagnostic to identify endometrial cancer patients eligible for immunotherapy

About 90,000 women globally die from endometrial cancer each year1 VENTANA MMR RxDx Panel is the first immunohistochemistry predictive test in endometrial cancer for treatment with the anti-PD1 immunotherapy JEMPERLI (dostarlimab-gxly) Roche/GSK collaboration represents an important step towards a personalised healthcare strategy that can help identify patients who are most likely to benefit from a... Read more

Expansion of Lonza’s Automated Robotic Solution for Endotoxin Testing Automates Sustainable Recombinant Factor C Assay

12 Apr 2021 Downloads News Release PDF The PyroTec® PRO Automated Solution combined with the PyroWave® Reader option expands the range of endotoxin testing types available on the platform to now include the PyroGene® Recombinant Factor C assay The addition of the PyroWave® XM Fluorescent Reader complements the existing absorbance readers used in traditional LAL-based assays Full integration with... Read more

Phase III prevention trial showed subcutaneous administration of investigational antibody cocktail casirivimab and imdevimab reduced risk of symptomatic COVID-19 infections by 81%

Among individuals who still experienced symptomatic infections, those who received casirivimab and imdevimab were able to clear the virus faster and had much shorter symptom duration In a cohort of recently-infected asymptomatic patients, casirivimab and imdevimab reduced the overall risk of progressing to symptomatic COVID-19 by 31% Detailed results will be shared with regulatory authorities... Read more

New phase III data shows investigational antibody cocktail casirivimab and imdevimab reduced hospitalisation or death by 70% in non-hospitalised patients with COVID-19

Investigational antibody cocktail of casirivimab and imdevimab also significantly shortened the duration of symptoms by four days The 2,400 mg and 1,200 mg doses tested in the phase III study had similar efficacy across all endpoints Companion dose-ranging phase II trial showed significant and comparable viral reductions for a range of doses of casirivimab and... Read more